True North Advisors LLC Has $2.30 Million Stake in Eli Lilly and Company $LLY

Key Points

• True North Advisors LLC reduced its stake in Eli Lilly and Company by 11.9%, owning 2,956 shares valued at approximately $2.30 million after selling 399 shares.
• Eli Lilly's stock has seen a recent fluctuation in analyst ratings, with several downgrades and an average target price of $939.61 according to MarketBeat.
• Executive vice president Daniel Skovronsky purchased 1,000 shares of Eli Lilly stock at about $634.40 each, raising his holdings to a total value of approximately $87.33 million.

True North Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,956 shares of the company's stock after selling 399 shares during the period. True North Advisors LLC's holdings in Eli Lilly and Company were worth $2,304,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Destiny Wealth Partners LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $624,000. ST Germain D J Co. Inc. increased its stake in Eli Lilly and Company by 10.7% in the 2nd quarter. ST Germain D J Co. Inc. now owns 1,846 shares of the company's stock valued at $1,439,000 after buying an additional 179 shares during the last quarter. FCG Investment Co increased its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. FCG Investment Co now owns 2,555 shares of the company's stock valued at $1,992,000 after buying an additional 48 shares during the last quarter. New Insight Wealth Advisors increased its stake in Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock valued at $307,000 after buying an additional 13 shares during the last quarter. Finally, Falcon Wealth Planning increased its stake in Eli Lilly and Company by 1.7% in the 2nd quarter. Falcon Wealth Planning now owns 984 shares of the company's stock valued at $767,000 after buying an additional 16 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Guggenheim lowered their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. Berenberg Bank reissued a "hold" rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $939.61.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $724.73 on Friday. The company has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 0.99 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a 50-day simple moving average of $734.15 and a 200 day simple moving average of $767.20. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.